Classification Term: 2239

2-heteroaryl carboxamides (ontology term: CHEMONTID:0004817)

Compounds containing a heteroaromatic ring that carries a carboxamide group." []

found 16 associated metabolites at family metabolite taxonomy ontology rank level.

Child Taxonomies: There is no child term of current ontology term.

Dacarbazine

Dacarbazine, Pharmaceutical Secondary Standard; Certified Reference Material

Dacarbazine appears as white to ivory microcrystals or off-white crystalline solid. (NTP, 1992) (E)-dacarbazine is a dacarbazine in which the N=N double bond adopts a trans-configuration. An antineoplastic agent. It has significant activity against melanomas. (from Martindale, The Extra Pharmacopoeia, 31st ed, p564). Dacarbazine with Oblimersen is in clinical trials for the treatment of malignant melanoma. Dacarbazine is an Alkylating Drug. The mechanism of action of dacarbazine is as an Alkylating Activity. Dacarbazine (also known as DTIC) is an intravenously administered alkylating agent used in the therapy of Hodgkin disease and malignant melanoma. Dacarbazine therapy has been associated with serum enzyme elevations during therapy and occasional cases of severe and distinctive acute hepatic failure, probably caused by acute sinusoidal obstruction syndrome. Dacarbazine is a triazene derivative with antineoplastic activity. Dacarbazine alkylates and cross-links DNA during all phases of the cell cycle, resulting in disruption of DNA function, cell cycle arrest, and apoptosis. (NCI04) An antineoplastic agent. It has significant activity against melanomas. (from Martindale, The Extra Pharmacopoeia, 31st ed, p564) Dacarbazine is only found in individuals that have used or taken this drug. It is an antineoplastic agent. It has significant activity against melanomas. (from Martindale, The Extra Pharmacopoeia, 31st ed, p564)The mechanism of action is not known, but appears to exert cytotoxic effects via its action as an alkylating agent. Other theories include DNA synthesis inhibition by its action as a purine analog, and interaction with SH groups. Dacarbazine is not cell cycle-phase specific. L - Antineoplastic and immunomodulating agents > L01 - Antineoplastic agents > L01A - Alkylating agents C274 - Antineoplastic Agent > C186664 - Cytotoxic Chemotherapeutic Agent > C2842 - DNA Binding Agent D009676 - Noxae > D000477 - Alkylating Agents D000970 - Antineoplastic Agents

5-(3-Methyl-1-triazeno)imidazole-4-carboxamide

5-(3-Methyl-1-triazeno)imidazole-4-carboxamide monohydrochloride

C5H8N6O (168.07595579999997)

D009676 - Noxae > D000477 - Alkylating Agents

1H-1,2,4-Triazole-3-carboxamide

1H-1,2,4-triazole-5-carboxamide

C3H4N4O (112.0385094)

1H-Imidazole-4-carboxamide

C4H5N3O (111.04326000000002)

2-Furamide

2,2-Dichloro-4-hydroxy-N-methylacetanilide 2-furoate

C5H5NO2 (111.032027)

D000890 - Anti-Infective Agents > D000977 - Antiparasitic Agents > D000981 - Antiprotozoal Agents

4-Amino-1H-imidazole-2-carboxamide

4-amino-3H-imidazole-2-carboxamide

C4H6N4O (126.05415860000001)

Allantoxanamide

4,6-dioxo-1,4,5,6-tetrahydro-1,3,5-triazine-2-carboxamide

C4H4N4O3 (156.0283394)

Etimizol

1-ethyl-N4,N5-dimethyl-1H-imidazole-4,5-dicarboxamide

C9H14N4O2 (210.1116704)

D002491 - Central Nervous System Agents > D018697 - Nootropic Agents

1-(2-Hydroxyethyl)-5-nitropyrrole-2-carboxamide

1-(2-hydroxyethyl)-5-nitro-1H-pyrrole-2-carboxamide

C7H9N3O4 (199.0593034)

D013501 - Surface-Active Agents > D011092 - Polyethylene Glycols D001697 - Biomedical and Dental Materials

Arg-3-hyp-7-phe-bradykinin

2-[(2-{[2-({2-[(2-{[2-({[1-(1-{2-[(2-amino-5-carbamimidamido-1-hydroxypentylidene)amino]-5-carbamimidamidopentanoyl}pyrrolidine-2-carbonyl)-4-hydroxypyrrolidin-2-yl](hydroxy)methylidene}amino)-1-hydroxyethylidene]amino}-1-hydroxy-3-phenylpropylidene)amino]-1,3-dihydroxypropylidene}amino)-1-hydroxy-3-phenylpropylidene]amino}-1-hydroxy-3-phenylpropylidene)amino]-5-carbamimidamidopentanoate

C60H87N19O13 (1281.6730412000002)

Rufinamide

1-[(2,6-difluorophenyl)methyl]-1H-1,2,3-triazole-4-carboxamide

C10H8F2N4O (238.06661419999998)

D002317 - Cardiovascular Agents > D026941 - Sodium Channel Blockers > D061567 - Voltage-Gated Sodium Channel Blockers N - Nervous system > N03 - Antiepileptics > N03A - Antiepileptics > N03AF - Carboxamide derivatives C78272 - Agent Affecting Nervous System > C264 - Anticonvulsant Agent D002491 - Central Nervous System Agents > D000927 - Anticonvulsants D049990 - Membrane Transport Modulators